The health care evolution whose time is now

–

Rethinking Health

The Health Optimizer Therapy Disruption

 👀 Get the insight 👀

Our latest RethinkX report explores how GLP-1 agonists and next-gen multi-agonist therapies are set to fundamentally transform human health.

As we enter a new era of “human optimization,” our roadmap provides investors and policymakers with a framework to navigate this inevitable disruption.

We invite you to explore the report and join our call for accelerated drug approval and universal free access.

KEY FINDINGS

💪 Mass Adoption by 2040 – Under medical guidance, over 1 billion adults globally will use personalized HOTs to optimize their health and wellbeing.

💪 “Diet & Exercise in a Bottle” – The first major breakthrough combines GLP-1s (weight loss) with myostatin inhibitors (muscle gain). This duo delivers the results medical science has chased for generations, with even more advanced therapies on the horizon.

💪 A Multi-Industry Earthquake – The disruption is inevitable and will ripple far beyond medicine. Major shifts are coming for food and beverage, agriculture, fitness, insurance, and even the alcohol and tobacco sectors.

💪 Global Prosperity Gains – Beyond individual health, widespread adoption promises massive social, economic, and geopolitical benefits, creating a healthier and more productive global society.

CALL TO ACTION

🚀 Nations should immediately enact policy to guarantee affordable, universal access to HOTs for all adults under the supervision of their doctor.

 

🚀 Nations should fast-track regulatory approval for the develop-ment of new HOTs drugs, to help ensure their enormous benefits reach the public as soon as possible.

Uncover ‘Rethinking Health’ Webpages 

Read the Executive Summary

Take a look at the implications for industry, health, social, geopolitical  environment,  and our interactive widgets.

“We want to hear your thoughts! Get in touch with questions, feedback, queries or partnership requests. Let’s get the word out about this transformational disruption.” –  Adam Dorr, RethinkX PhD. Director of Research